Compare General Motors Company (GM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs State Street SPDR S&P Biotech ETF — how do they compare? General Motors Company trades at $82.73 (market cap $72.17B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: General Motors Company is far larger — about 7.1× State Street SPDR S&P Biotech ETF's market cap, and General Motors Company pays a 0.88% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GM | XBI | |
|---|---|---|
Market Cap | $72.17B | $10.11B |
Volume | 4,900,304 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $90.30 | $169.55 |
52-Week Low | $55.35 | $104.99 |
Typical Hold Time | 83 Days | 38 Days |
Enterprise Value | $175.15B | — |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.25, up 1.56% with a bearish technical signal despite beating earnings estimates for three consecutive quarters. The company faces declining vehicle sales (-5.5% in Q3 2026) and margin pressure, with net income margin at 1.05%. Analyst consensus remains bullish with a $102.17 price target, though cash flow trends show volatility with projected negative net cash flow in 2026.
GM's valuation appears reasonable (P/S 0.42, P/B 1.16) but profitability concerns persist amid sales declines and EV challenges. Near-term risks include competitive pressure from Asian automakers and high gasoline prices, while regulatory savings ($20.4B from eased fuel rules) offer partial offset. The stock presents a value opportunity if execution improves.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
